450. Costs of routine care for chronic hepatitis C virus infection: the case of Illinois Medicaid
Session: Poster Abstract Session: Hepatitis C
Thursday, October 27, 2016
Room: Poster Hall

Background: Expenditures associated with untreated hepatitis C (HCV) and its complications impact state Medicaid budgets and should be quantified to inform reimbursement policies for HCV therapy. We determined the service utilization and costs associated with HCV with and without advanced liver disease (ALD) in Illinois Medicaid beneficiaries.

Methods: Population-based descriptive and retrospective case-control study using administrative data from the Illinois Medicaid fee-for-service program, 2006-2009. Cases were aged 18-64y with untreated HCV, stratified by presence or absence of ALD. Controls were uninfected patients, matched to cases based on age, sex, race, enrollment time, co-morbidity and geography characteristics. We calculated adjusted all-cause per-person per-month costs (PPPM), health service utilization including hospitalization, emergency room use, outpatient visits and receipt of long-term care, and unadjusted total 4-year all-cause expenditures.

Results: We identified 9,903 patients with untreated HCV infection, and matched 9,571 cases (96.6%) to 172,886 un-infected controls. The prevalence of HCV was 1.2%. HCV infection without and with ALD was associated with increased service utilization and cost compared to non-infected matched controls. Mean adjusted all-cause PPPM costs among persons with HCV and matched controls without HCV were $3,012 and $1,604, respectively (p < 0.001). In stratified analysis, costs for HCV cases without ALD were nearly twice that of non-infected controls ($2,222 vs $1,192, p <0.001). Costs for HCV cases with ALD compared to non-infected controls were likewise higher ($6,725 vs $3,521, p < 0.001). Cases with ALD comprised 24% of the HCV-infected population while accounting for 40% of total spending.

Conclusion: HCV and HCV-associated ALD generate substantial cost for IL Medicaid. Treating HCV before patients become cirrhotic could prevent substantial service utilization and costs.

Mai T. Pho, MD MPH1, Yue Gao, MPH2, Joshua Salomon, PHD3, Elbert Huang, MD MPH2, Robert Nocon, MHS2, Jake Morgan, MS4, Laura White, PHD5 and Benjamin Linas, MD, MPH6, (1)Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago, Chicago, IL, (2)Medicine, University of Chicago, Chicago, IL, (3)Global Health, Harvard T.H. Chan School of Public Health, Boston, MA, (4)Boston University School of Public Health, Boston, MA, (5)Biostatistics, Boston University School of Public Health, Boston, MA, (6)Internal Medicine, Section of Infectious Disease, Boston Medical Center, Boston University School of Medicine, Boston, MA

Disclosures:

M. T. Pho, None

Y. Gao, None

J. Salomon, None

E. Huang, None

R. Nocon, None

J. Morgan, None

L. White, None

B. Linas, None

See more of: Hepatitis C
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.